Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | IL1B | P01584 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998249 | 0.89 | DDB1 (0.55) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL21997094 | 0.81 | CRBN (0.58) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL21997211 | 0.81 | CRBN (0.59) | DDB1CRBNSTAT3 | |
| SCHEMBL24926192 | 0.77 | DDB1 (0.61) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL22836315 | 0.77 | CRBN (0.54) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL29856105 | 0.77 | DDB1 (0.66) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL27196441 | 0.77 | DDB1 (0.66) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL15559912 | 0.77 | DDB1 (0.82) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL16569284 | 0.77 | DDB1 (0.82) | DDB1CRBNTNFIL1BTBXA2R | |
| SCHEMBL18546682 | 0.77 | DDB1 (0.82) | DDB1CRBNTNFIL1BTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885TNF 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.